Wall Street Loves this New Immunotherapy Cancer Drug

As new immunotherapy drugs hope to turn metastatic cancer into a chronic manageable condition, or at least significantly prolong life in the near term, investors are understandably excited about their potential.

And one company at the forefront of this move, Bristol-Myers Squibb, just got a huge upgrade today from Wall Street titan Citigroup, sending shares 5% higher. Citi moved Bristol from "neutral" to "buy" and upped its old $33 price target to $55 per share.

In this video, health-care analyst David Williamson discusses Bristol's big upgrade and gives a few of his key takeaways from the report.

Another topic health care investors need to keep up on is Obamacare, as the law will undoubtedly have far-reaching effects. The Motley Fool's new free report, "Everything You Need to Know About Obamacare," lets you know how your health insurance, your taxes, and your portfolio will be affected. Click here to read more. 

Follow David on Twitter: @MotleyDavid.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2448274, ~/Articles/ArticleHandler.aspx, 4/24/2014 7:15:06 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement